HYL.BR
Strong SellSinkerHyloris Pharmaceuticals SA · Healthcare · Belgium · $143M · Avg Vol: $9K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
14
StockRankGet insider-trade alerts
QualityQuality
32
ValueValue
25
MomentumMomentum
34
P/E (TTM)
—
peers 18.4x
ROE
-21.6%
peers 10.9%
D/E
0.1x
peers 0.5x
Dividend %
—
trailing yield
ABOUT HYLORIS PHARMACEUTICALS SA
Read
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0.9M | 2.1M | 8.5M | 7.2M | 100.1% | 7.9M | 18.0M | — | 149.6% |
| EPS (EUR) | -0.45 | -0.43 | -0.56 | -0.23 | -0.23 | — | -0.23 | -0.33 | 0.45 | — |
| Shares | — | 28.0M | 28.0M | 28.0M | 28.0M | 0.0% | 28.0M | — | — | — |
| Debt | — | 0.9M | 1.8M | 1.8M | 1.6M | 22.1% | 1.6M | — | — | — |
| Equity | — | 53.9M | 39.1M | 32.1M | 26.5M | -21.1% | — | — | — | — |
| Op CF | — | -13.0M | -12.8M | -7.2M | -7.0M | — | -7.0M | — | — | — |
| Inv CF | — | -11.4M | 9.9M | 0.7M | -2.1M | — | — | — | — | — |
| Fin CF | — | 7.8M | -0.1M | -0.4M | -0.4M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-9.6%
SMA 50SMA 200
Close
$4.88
RSI (14)
39.4
52W High
$9.65
From 52W High
0.5%
SCORE BREAKDOWN
Quality
32
ROIC
-23.5%27.5
ROE
-21.6%29.3
GP/Assets
22.5%49.4
Op. Margin
-100.5%17.0
FCF/Assets
-22.8%18.5
Piotroski
25.9
Int. Cover
-50.0x5.9
D/E Ratio
0.06x69.0
Current Ratio
3.89x65.1
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-13.1x25.0
P/FCF
—N/A
P/B
4.4x31.4
P/S
14.8x19.4
Div Yield
—N/A
Momentum
34
52W High %
51%24.4
RS 6M
-41%21.3
SMA 50/200
0.81x16.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+293%91.8
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$143M
P/E (Forward)
9.4x
Gross Margin
95.2%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HYL.BR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HYL.BR | Hyloris Pharmaceuticals SA(you) | $143M | 14 | Strong Sell |
| AGMB | AgomAb Therapeutics NV | $649M | 14 | Strong Sell |
| TUB.BR | Financière de Tubize SA | $9.6B | 29 | Sell |
| LKFT | Lakefront Biotherapeutics NV | $1.9B | 68 | Buy |
| NYXH | Nyxoah SA | $163M | 10 | Strong Sell |
| MDXH | MDxHealth SA | $69M | 13 | Strong Sell |
| SEQUA.BR | Sequana Medical NV | $54M | 13 | Strong Sell |
| UCB.BR | UCB SA | $47.8B | 79 | Buy |
| IBAB.BR | Ion Beam Applications SA | $567M | 71 | Buy |
| FAGR.BR | Fagron NV | $1.9B | 83 | Strong Buy |
Peer medians: ROE 10.9% · P/E 18.4x · Gross margin 60.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.